SCHEMBL2983229

SCHEMBL2983229

CC[C@@](O)(c1cnc(Sc2ccc3c(-c4cccnc4)cc(=O)oc3c2)s1)C(F)(F)F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 2/20 0.55
ALOX5 P09917 8/20 0.44
NPC1 O15118 1/20 0.39
TNF P01375 1/20 0.39
POLB P06746 1/20 0.39
RAB9A P51151 1/20 0.39
NOD1 Q9Y239 1/20 0.39
KCNA3 P22001 1/20 0.35
GAA P10253 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 2/20 0.34
USP2 O75604 1/20 0.34
CA12 O43570 2/20 0.33
CA9 Q16790 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ALDH2 P05091 1/20 0.33
AKR1B1 P15121 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2989716 1.00 MLYCD (0.55) MLYCDALOX5NPC1TNFPOLB
SCHEMBL2977269 0.93 MLYCD (0.57) MLYCDALOX5ALDH1A1HPGDUSP2
SCHEMBL2977271 0.93 MLYCD (0.57) MLYCDALOX5ALDH1A1HPGDUSP2
SCHEMBL2986065 0.90 MLYCD (0.52) MLYCDALOX5NPC1TNFPOLB
SCHEMBL2983995 0.89 MLYCD (0.55) MLYCDALOX5KCNA3ALDH1A1HPGD
SCHEMBL2983994 0.89 MLYCD (0.55) MLYCDALOX5KCNA3ALDH1A1HPGD
SCHEMBL2990150 0.89 MLYCD (0.56) MLYCDALOX5RAB9ATDP1ALDH1A1
SCHEMBL2991945 0.89 MLYCD (0.69) MLYCDALOX5NPC1TNFPOLB
SCHEMBL2979616 0.88 MLYCD (0.57) MLYCDALOX5TDP1ALDH1A1HPGD
SCHEMBL2987497 0.88 MLYCD (0.57) MLYCDALOX5ALDH1A1HPGDCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7439260-B2 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors MERCK FORSST CANADA & CO. (CA) 2008-10-21 US claimed
US-20060116406-A1 7-(1,3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors GAREAU YVES 2006-06-01 US claimed
US-20100137371-A1 Novel Pharmaceutical Compounds MERCK FROSST CANADA LTD. (CA) 2010-06-03 US disclosed
US-20100137371-A1 Novel Pharmaceutical Compounds MERCK FROSST CANADA LTD. (CA) 2010-06-03 US disclosed
US-20100137371-A1 Novel Pharmaceutical Compounds MERCK FROSST CANADA LTD. (CA) 2010-06-03 US disclosed
US-7439260-B2 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors MERCK FORSST CANADA & CO. (CA) 2008-10-21 US disclosed
US-7439260-B2 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors MERCK FORSST CANADA & CO. (CA) 2008-10-21 US disclosed
US-7439260-B2 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors MERCK FORSST CANADA & CO. (CA) 2008-10-21 US disclosed
US-20060116406-A1 7-(1,3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors GAREAU YVES 2006-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116406-A1 7-(1,3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors LTC4S, LTA4H, CYSLTR1 MLYCD 2142/4885ALOX5 17/4885NPC1 497/4885
US-20100137371-A1 Novel Pharmaceutical Compounds LTC4S, LTA4H, LTB4R2 MLYCD 2597/4885ALOX5 17/4885NPC1 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.